Skip Navigation



Annals of Oncology Advance Access published online on May 19, 2005
Annals of Oncology, doi:10.1093/annonc/mdi238
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/8/1381    most recent
mdi238v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Krüger, W. H.
Right arrow Articles by Wolf, H.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krüger, W. H.
Right arrow Articles by Wolf, H.-H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology
Received February 9, 2005
Accepted March 3, 2005

Original article

Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Oncology

W. H. Krüger 1*, J. Bohlius 2, O. A. Cornely 2, H. Einsele 3, H. Hebart 3, G. Massenkeil 4, S. Schüttrumpf 5, G. Silling 6, A. J. Ullmann 7, D. T. Waldschmidt 8, and H.-H. Wolf 9

1 Medizinische Klinik C, Greifswald, Germany
2 Klinik I für Innere Medizin, Klinische Infektiologie, Klinikum der Universität zu Köln, Köln, Germany
3 Medizinische Klinik II, Abt. Hämatologie/Onkologie/Immunologie, Eberhard-Karls-Universität, Tübingen, Germany
4 Klinik für Hämatologie und Onkologie,Universitätsklinik Charité, Campus Virchow-Klinikum, Berlin, Germany
5 Zentrum Innere Medizin, Abteilung für Hämatologie/Onkologie, Georg-August-Universität Göttingen, Göttingen, Germany
6 Medizinische Klinik A - KMT-Zentrum, Westfälische-Wilhelms-Universität, Münster, Germany
7 Medizinische Klinik und Poliklinik, Klinikum der Johannes Gutenberg-Universität, Mainz, Germany
8 Klinik IV für Innere Medizin, Klinikum der Universität zu Köln
9 Klinik für Innere Medizin IV, Martin-Luther-Universität Halle-Wittenberg, Halle (Saale), Germany

* To whom correspondence should be addressed.
W. H. Krüger, E-mail: william.krueger{at}uni-greifswald.de


  Abstract

Patients undergoing allogeneic stem cell transplantation are at high risk for infection with a variety of pathogens during different phases of the procedure. Bacteria and fungi predominate the first phase until engraftment. During the second phase, from engraftment to about day 100, major infectious problems are caused by fungi and cytomegalovirus. Both pathogens remain important under continued immunosuppression, however, in the late post-transplantation period infections with encapsulated bacteria may become a problem. In this review the Infectious Diseases Working Party of the DGHO gives recommendations for prophylaxis of infections under allogeneic stem cell transplantation with drugs and other measures. The aim of the group was to do this on an evidence-based-medicine rating, if possible.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
G. Brandi, J. Dabard, P. Raibaud, M. Di Battista, C. Bridonneau, A. M. Pisi, A. M. M. Labate, M. A. Pantaleo, A. De Vivo, and G. Biasco
Intestinal Microflora and Digestive Toxicity of Irinotecan in Mice
Clin. Cancer Res., February 15, 2006; 12(4): 1299 - 1307.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.